Granules India gets license from DRDO for Covid drug 2-DG

Granules is working closely with DRDO team to launch the product in India at the earliest,” it added.

54
DRDO

Last Updated on September 5, 2021 by The Health Master

Granules India yesterday said it has received licence from Defence Research and Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

Granules is working closely with DRDO team to launch the product in India at the earliest,” it added.

The drug reduces a patient’s average recovery time by two and half days and oxygen demand by up to 40 per cent, the filing said.

Govt amends New Drugs & Clinical Trial Rules 2019

NPPA panel recommends 15% rise in ceiling price for 3 formulations

DCGI gives nod for Vaccine’s phase-II/III trials on kids aged between…

Kudos to Gujarat FDCA for Covaxin facility: Bharat Biotech

How to test if green labelled package is pure veg? High…

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner